Analysts chose stocks from pharmaceutical, power, automobile, and consumer segments for Wednesday's 'buy' recommendations.
Adlytick.in Founder and Multi Asset Research Analyst Aditya Arora, Invest4edu Research And Investments Head Aditya Agarwala, and Reliance Securities Research Head Vikas Jain shared their views on above mentioned stocks.
For more live stock recommendations click here.
Gillette India
Adlytick.in's Aditya Arora suggested buying Gillette India Ltd. The target price is Rs 10,172 apiece, which implied a 5.8% upside from Tuesday's closing price. The stop loss is at Rs 9,600 apiece.
Two analysts tracking the company maintain a 'buy' rating, according to Bloomberg data. The average 12-month consensus price target implies an upside of 1.1%.
Eris Lifesciences
Arora suggested a buy for the stock. The target price is Rs 1,752 apiece, which implied 4.1% upside from Tuesday's close price. The stop loss is at Rs 1,632 apiece.
Out of 11 analysts tracking the company, 10 maintain a 'buy' rating, and one recommends a 'hold', according to Bloomberg data. The average 12-month consensus price target implies a downside of 2.7%.
Tata Motors
Invest4edu's Aditya Agarwala suggested a buy for the stock. The target price is Rs 785 apiece, which implied a 7.1% upside from Tuesday's close price. The stop loss is at Rs 700 apiece.
Out of 35 analysts tracking the company, 18 maintain a 'buy' rating, 11 recommend a 'hold' and six suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 3.0%.
Power Grid Corp.
Power Grid Corp. of India got a buy recommendation from Invest4edu. The target price for the stock is Rs 325 apiece, which implied 8% upside from Tuesday's close price. The stop loss is at Rs 290 apiece.
Out of 24 analysts tracking the company, 16 maintain a 'buy' rating, two recommend a 'hold' and six suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 7.0%.
Mankind Pharma
Reliance Securities' Vikas Jain gave a buy recommendation for Mankind Pharma Ltd. The target price was Rs 2,650, which implied an 11% upside from Tuesday's close price. The stop loss was at Rs 2,250 apiece.
Out of 16 analysts tracking the company, 12 maintain a 'buy' rating, two recommend a 'hold', and two suggest 'sell', according to Bloomberg data. The average 12-month consensus price target implies an upside of 14.2%.
Disclaimer: The views and opinions expressed by the investment advisers are of their own and not of NDTV Profit. NDTV Profit advises readers to consult their financial advisers before investment.
Comprehensive Budget 2026 coverage, LIVE TV analysis, Stock Market and Industry reactions, Income Tax changes and Latest News on NDTV Profit.
